Orphan designation: Serplulimab Treatment of small cell lung cancer, 20/02/2025 Positive
Serplulimab belongs to the class of:Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants This medicine is a fully humanized IgG4 monoclonal antibody, a type of protein that has been designed to attach …